Changshan ConjuChem BioPharmaceutical Research and Development

Changshan ConjuChem is a biopharmaceutical joint venture established by Hebei Changshan Biochemical Pharmaceutical and the North American biotech ConjuChem LLC. The company focuses on developing long-acting biopharmaceuticals using the proprietary Drug Affinity Complex (DAC) technology, which enables therapeutic peptides to covalently bond with recombinant human albumin to extend their half-life. Its lead candidate, Ebenatide (CJC-1134-PC), is a weekly GLP-1 receptor agonist that has successfully completed Phase 3 clinical trials in China for the treatment of type 2 diabetes. The company operates research, development, and manufacturing facilities in Zhejiang Province, aiming to address chronic metabolic diseases with improved patient compliance. Changshan ConjuChem represents a strategic collaboration to bring advanced albumin-binding drug delivery platforms to the Chinese market.